{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"12.5","value":"9.1"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"9.4","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Overall survival was defined as time from registration on step 1 to death from any cause. It was evaluated in all 61 eligible and treated patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Bortezomib+Irinotecan)"},{"description":"Patients receive bortezomib (PS-341) 1.3 mg/m2 IV over 3-5 seconds twice weekly on days 1, 4, 8 and 11 followed by one week of rest. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I (bortezomib + irinotecan).","id":"OG001","title":"Arm II (Bortezomib)"}],"paramType":"MEDIAN","populationDescription":"61 eligible and treated patients were included in the analysis","reportingStatus":"POSTED","timeFrame":"Survival was assessed every 3 month within 2 years and every 6 months betwen 2 and 3 years","title":"Overall Survival on Step 1","type":"SECONDARY","unitOfMeasure":"months"}